Ph.D. Niro Ramachandran - 15 Feb 2023 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role: Chief Business Officer
Signature: /s/ Niro Ramachandran, Ph.D., by Brian McKelligon, as Attorney-in-Fact
Issuer symbol: AKYA
Transactions as of: 15 Feb 2023
Net transactions value: +$30,940
Form type: 4
Filing time: 17 Feb 2023, 16:10:20 UTC
Previous filing: 14 Apr 2022
Next filing: 27 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKYA	Common Stock	Options Exercise	$30,940	+34,000	+28%	$0.9100^*	156,680	15 Feb 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKYA	Employee Stock Option (Right to Buy)	Options Exercise	$0	-34,000	-35%	$0.000000	62,566	15 Feb 2023	Common Stock	34,000	$0.9100	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option vested as follows: one-fourth (1/4) of the shares on July 13, 2021 and the remaining shares shall vest in 36 equal monthly installments beginning on July 13, 2021, until fully vested, subject to reporting person's continuous employment.